Skip to Main content Skip to Navigation
New interface

Variabilité pharmacocinétique des anti-cancéreux : Application à la vinorelbine et au lapatinib

Abstract : The identification of sources of pharmacokinetic and / or pharmacodynamic variabilities, optimizes the use of cytotoxic agents. The combination of targeted therapies with conventional drugs may provide additional benefits in terms of therapeutic benefit, but also can cause drug interactions and increased variability. Drug interactions are known to have a significant impact on drug disposition.The first part of this work is to measure blood concentrations of two molecules (lapatinib and vinorelbine) in patients and to perform pharmacokinetic modeling. This modeling clearly showed the influence of weight and the platelet number on the pharmacokinetics of vinorelbine reducing thereby the pharmacokinetic variabilities. It also highlighted the influence of lapatinib on the pharmacokinetics of vinorelbine. However, due to the lack of control group, we failed to obtain statistical significance for these results. In parallel, no effect of vinorelbine on the pharmacokinetics of lapatinib has been detected.The second part concerns the modeling of the response and tolerance of patients for this drug combination (pharmacodynamic modeling). Neutropenia was detected as the dose-limiting toxicity of the combination and the fact that lapatinib is not known to be myelotoxic, we performed toxicity modeling based on the pharmacokinetics of vinorelbine. Again, we observed a strong tendency on the influence of lapatinib on the myelotoxicity of vinorelbine. Regarding the efficacy of this combination, tumor growth modeling showed a synergistic action between the two molecules. To our knowledge this is the first time that such a model, both in terms of tolerance and response, is implemented in a combination of conventional chemotherapy and targeted therapy.Population PK-PD modeling of cancer drugs can provide valuable assistance to clinicians in this field. It can also be essential in the early clinical decision making.
Document type :
Complete list of metadata

Cited literature [89 references]  Display  Hide  Download
Contributor : ABES STAR :  Contact
Submitted on : Friday, July 13, 2012 - 9:47:30 AM
Last modification on : Thursday, October 20, 2022 - 9:06:57 AM
Long-term archiving on: : Sunday, October 14, 2012 - 2:30:17 AM


Version validated by the jury (STAR)


  • HAL Id : tel-00717480, version 1



Keyvan Rezai Gharahbolagh. Variabilité pharmacocinétique des anti-cancéreux : Application à la vinorelbine et au lapatinib. Médecine humaine et pathologie. Université René Descartes - Paris V, 2012. Français. ⟨NNT : 2012PA05P606⟩. ⟨tel-00717480⟩



Record views


Files downloads